Leo Feferman1,2, Ryan Deaton3, Sumit Bhattacharyya1,2, Hui Xie4, Peter H Gann3, Jonathan Melamed5, Joanne K Tobacman1,2. 1. Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA. 2. Jesse Brown VA Medical Center, Chicago, IL, USA. 3. Department of Pathology, University of Illinois at Chicago, Chicago, IL, USA. 4. Center for Clinical and Translational Sciences and Department of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL, USA. 5. Department of Pathology, New York University Langone Medical Center, New York, NY, USA.
Abstract
BACKGROUND: Arylsulfatase B (ARSB) removes the 4-sulfate group from chondroitin 4-sulfate (C4S) and dermatan sulfate and is required for their degradation. Prior work showed that ARSB immunohistochemical scores were lower in malignant prostate tissue, and were associated with higher Gleason scores and recurrence. OBJECTIVE: This study aims to confirm that ARSB immunostaining of prostate tissue obtained at the time of radical prostatectomy is prognostic for prostate cancer recurrence. METHODS: Intensity and distribution of ARSB immunostaining were digitally analyzed in a large, well-annotated, prostate cancer tissue microarray (TMA). Scores were calculated for stroma and epithelium and compared for 191 cases, including 36 recurrences, defined as PSA > 0.2 ng/ml. RESULTS: Epithelial scores were significantly lower in the recurrences (p= 0.010), and among subgroups with age > 60, initial PSA > 6 ng/ml, or Gleason grade = 7. ARSB score did not improve the prediction of recurrence in multifactorial analysis. CONCLUSIONS: Study findings validate previous findings and provide further evidence that lower ARSB is associated with prostate cancer recurrence. Additional studies are required to assess if there are specific cutoff values that may help predict recurrence.
BACKGROUND:Arylsulfatase B (ARSB) removes the 4-sulfate group from chondroitin 4-sulfate (C4S) and dermatan sulfate and is required for their degradation. Prior work showed that ARSB immunohistochemical scores were lower in malignant prostate tissue, and were associated with higher Gleason scores and recurrence. OBJECTIVE: This study aims to confirm that ARSB immunostaining of prostate tissue obtained at the time of radical prostatectomy is prognostic for prostate cancer recurrence. METHODS: Intensity and distribution of ARSB immunostaining were digitally analyzed in a large, well-annotated, prostate cancer tissue microarray (TMA). Scores were calculated for stroma and epithelium and compared for 191 cases, including 36 recurrences, defined as PSA > 0.2 ng/ml. RESULTS: Epithelial scores were significantly lower in the recurrences (p= 0.010), and among subgroups with age > 60, initial PSA > 6 ng/ml, or Gleason grade = 7. ARSB score did not improve the prediction of recurrence in multifactorial analysis. CONCLUSIONS: Study findings validate previous findings and provide further evidence that lower ARSB is associated with prostate cancer recurrence. Additional studies are required to assess if there are specific cutoff values that may help predict recurrence.
Authors: Chris Kedong Wang; Htoo Zarni Oo; Nader Al-Nakouzi; Irina Nelepcu; Nada Lallous; Charlotte B Spliid; Nastaran Khazamipour; Joey Lo; Sarah Truong; Colin Collins; Desmond Hui; Shaghayegh Esfandnia; Hans Adomat; Thomas Mandel Clausen; Tobias Gustavsson; Swati Choudhary; Robert Dagil; Eva Corey; Yuzhuo Wang; Anne Chauchereau; Ladan Fazli; Jeffrey D Esko; Ali Salanti; Peter S Nelson; Martin E Gleave; Mads Daugaard Journal: Nat Commun Date: 2022-08-13 Impact factor: 17.694